[go: up one dir, main page]

FR3081325B1 - Diltiazem pour son utilisation dans le traitement des infections microbiennes - Google Patents

Diltiazem pour son utilisation dans le traitement des infections microbiennes Download PDF

Info

Publication number
FR3081325B1
FR3081325B1 FR1854307A FR1854307A FR3081325B1 FR 3081325 B1 FR3081325 B1 FR 3081325B1 FR 1854307 A FR1854307 A FR 1854307A FR 1854307 A FR1854307 A FR 1854307A FR 3081325 B1 FR3081325 B1 FR 3081325B1
Authority
FR
France
Prior art keywords
diltiazem
treatment
microbial infections
infections
epithelia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1854307A
Other languages
English (en)
Other versions
FR3081325A1 (fr
Inventor
Manuel Rosa-Calatrava
Olivier Terrier
De Lamballerie Claire Nicolas
Guy Boivin
Mario Andres Pizzorno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Laval
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Ecole Normale Superieure de Lyon
Universite Claude Bernard Lyon 1
Original Assignee
Universite Laval
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Ecole Normale Superieure de Lyon
Universite Claude Bernard Lyon 1
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1854307A priority Critical patent/FR3081325B1/fr
Application filed by Universite Laval, Centre National de la Recherche Scientifique CNRS, Institut National de la Sante et de la Recherche Medicale INSERM, Ecole Normale Superieure de Lyon, Universite Claude Bernard Lyon 1 filed Critical Universite Laval
Priority to US17/057,141 priority patent/US12285433B2/en
Priority to CA3101006A priority patent/CA3101006A1/fr
Priority to KR1020207036694A priority patent/KR102859532B1/ko
Priority to CN201980047805.2A priority patent/CN112789046B/zh
Priority to MX2020012543A priority patent/MX2020012543A/es
Priority to AU2019273741A priority patent/AU2019273741A1/en
Priority to EP19737813.6A priority patent/EP3796916A1/fr
Priority to BR112020023675-6A priority patent/BR112020023675A2/pt
Priority to JP2020565368A priority patent/JP7412353B2/ja
Priority to PCT/FR2019/051186 priority patent/WO2019224489A1/fr
Publication of FR3081325A1 publication Critical patent/FR3081325A1/fr
Application granted granted Critical
Publication of FR3081325B1 publication Critical patent/FR3081325B1/fr
Priority to IL278895A priority patent/IL278895A/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne le diltiazem pour son utilisation en tant qu'agent activateur de l'expression d'au moins un gène codant pour un interféron de type III, dans la prévention et/ou le traitement des infections par au moins un microorganisme pathogène des épitheliums des tractus respiratoires et/ou intestinaux.
FR1854307A 2018-05-23 2018-05-23 Diltiazem pour son utilisation dans le traitement des infections microbiennes Active FR3081325B1 (fr)

Priority Applications (12)

Application Number Priority Date Filing Date Title
FR1854307A FR3081325B1 (fr) 2018-05-23 2018-05-23 Diltiazem pour son utilisation dans le traitement des infections microbiennes
BR112020023675-6A BR112020023675A2 (pt) 2018-05-23 2019-05-23 diltiazem para uso no tratamento de infecções microbianas
KR1020207036694A KR102859532B1 (ko) 2018-05-23 2019-05-23 미생물 감염의 치료에서 사용을 위한 딜티아젬
CN201980047805.2A CN112789046B (zh) 2018-05-23 2019-05-23 地尔硫卓用于治疗微生物感染
MX2020012543A MX2020012543A (es) 2018-05-23 2019-05-23 Diltiazem para usarse en el tratamiento de infecciones microbianas.
AU2019273741A AU2019273741A1 (en) 2018-05-23 2019-05-23 Diltiazem for use in the treatment of microbial infections
US17/057,141 US12285433B2 (en) 2018-05-23 2019-05-23 Diltiazem for use in the treatment of microbial infections
CA3101006A CA3101006A1 (fr) 2018-05-23 2019-05-23 Diltiazem pour son utilisation dans le traitement des infections microbiennes
JP2020565368A JP7412353B2 (ja) 2018-05-23 2019-05-23 微生物感染の治療における使用のためのジルチアゼム
PCT/FR2019/051186 WO2019224489A1 (fr) 2018-05-23 2019-05-23 Diltiazem pour son utilisation dans le traitement des infections microbiennes
EP19737813.6A EP3796916A1 (fr) 2018-05-23 2019-05-23 Diltiazem pour son utilisation dans le traitement des infections microbiennes
IL278895A IL278895A (en) 2018-05-23 2020-11-22 Diltiazem for use in the treatment of microbial infections

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1854307A FR3081325B1 (fr) 2018-05-23 2018-05-23 Diltiazem pour son utilisation dans le traitement des infections microbiennes
FR1854307 2018-05-23

Publications (2)

Publication Number Publication Date
FR3081325A1 FR3081325A1 (fr) 2019-11-29
FR3081325B1 true FR3081325B1 (fr) 2020-10-09

Family

ID=63145035

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1854307A Active FR3081325B1 (fr) 2018-05-23 2018-05-23 Diltiazem pour son utilisation dans le traitement des infections microbiennes

Country Status (12)

Country Link
US (1) US12285433B2 (fr)
EP (1) EP3796916A1 (fr)
JP (1) JP7412353B2 (fr)
KR (1) KR102859532B1 (fr)
CN (1) CN112789046B (fr)
AU (1) AU2019273741A1 (fr)
BR (1) BR112020023675A2 (fr)
CA (1) CA3101006A1 (fr)
FR (1) FR3081325B1 (fr)
IL (1) IL278895A (fr)
MX (1) MX2020012543A (fr)
WO (1) WO2019224489A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3106055B1 (fr) 2020-01-13 2022-01-28 Centre Nat Rech Scient Combinaison de diltiazem et autres agents antiviraux
FR3108033B1 (fr) 2020-03-10 2023-04-21 Univ Claude Bernard Lyon COMPOSES ANTIVIRAUX ET LEURS COMBINAISONS POUR TRAITER L’INFECTION VIRALE PAR LE SARS-CoV-2
CN117625480B (zh) * 2023-11-30 2024-05-31 吉林农业大学 一株粪肠球菌及其在抗猪轮状病方面的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3326089A1 (de) 1983-07-20 1985-02-07 Gödecke AG, 1000 Berlin Zur inhalation bestimmte darreichungsform von calcium-antagonisten
US4849412A (en) 1986-06-05 1989-07-18 Board Of Regents, The University Of Texas System Methods and compositions for treating viral infections
FR2784030B1 (fr) 1998-10-02 2002-12-20 Inst Nat Sante Rech Med Utilisation de bloqueurs des canaux calciques et/ou cgmp-dependants pour le traitement de pathologies de la retine
WO2002094238A1 (fr) 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Apport de composes anti-migraine par voie d'inhalation
US20060198823A1 (en) * 2003-04-04 2006-09-07 Blatt Lawrence M Compositions and methods for treating viral infections
WO2005007082A2 (fr) * 2003-06-03 2005-01-27 Wisys Technology Foundation, Inc. Traitement d'infections bacteriennes chroniques et pathologies correspondantes
EP1755615B1 (fr) 2004-04-22 2013-11-27 Howard J. Smith & Associates Pty Ltd Traitement de soutien d'une maladie du foie
DK2315580T3 (da) * 2009-03-26 2012-04-10 Pulmatrix Inc Farmaceutiske formuleringer og fremgangsmåder til behandling af luftvejsinfektioner
CA3013734C (fr) 2009-12-03 2020-01-14 Dr. Kenneth Adams Medicine Professional Corporation Methode et composition destinees au traitement et a la prevention d'une vaste gamme d'affections virales
JP2013139391A (ja) * 2010-04-09 2013-07-18 Hokkaido Univ ウイルス感染抑制および／または感染症治療剤
EP3233069A1 (fr) * 2014-12-18 2017-10-25 Helperby Therapeutics Limited Combinaison antimicrobiennes et leur utilisation dans le traitement d'infection microbienne
FR3033701B1 (fr) 2015-03-19 2021-01-15 Univ Claude Bernard Lyon Nouvelles compositions antivirales pour le traitement de la grippe
US11197904B2 (en) * 2018-01-23 2021-12-14 Shoei-Yn Lin-Shiau Pharmaceutical compositions for preventions and managements of dementia, infectious diseases, cancers, periodontitis, dental caries, diabetes, obesity, osteoporosis and chronic pain and methods thereof

Also Published As

Publication number Publication date
CN112789046B (zh) 2024-02-20
IL278895A (en) 2021-01-31
MX2020012543A (es) 2021-05-13
BR112020023675A2 (pt) 2021-02-17
KR20210013136A (ko) 2021-02-03
KR102859532B1 (ko) 2025-09-12
WO2019224489A1 (fr) 2019-11-28
AU2019273741A1 (en) 2020-12-24
FR3081325A1 (fr) 2019-11-29
CN112789046A (zh) 2021-05-11
JP7412353B2 (ja) 2024-01-12
CA3101006A1 (fr) 2019-11-28
US20210154205A1 (en) 2021-05-27
JP2021525250A (ja) 2021-09-24
EP3796916A1 (fr) 2021-03-31
US12285433B2 (en) 2025-04-29

Similar Documents

Publication Publication Date Title
MA53937A (fr) Compositions comprenant des souches bactériennes
FR3057773B1 (fr) Nouvelles compositions antivirales pour le traitement des infections liees aux coronavirus
MA40755B1 (fr) Compositions comprenant des souches bactériennes
MA40754B1 (fr) Compositions comprenant des souches bactériennes
MA41060A (fr) Compositions comprenant des souches bactériennes
MA55434B1 (fr) Compositions comprenant des souches bactériennes
MA41010A (fr) Compositions comprenant des souches bactériennes
FR3081325B1 (fr) Diltiazem pour son utilisation dans le traitement des infections microbiennes
MA43113B1 (fr) Anticorps anti-htr a1 et méthodes d'utilisation de ceux-ci
MA52216B1 (fr) Mirikizumab pour le traitement de la colite ulcéreuse
FR3084255B1 (fr) Souche de streptococcus thermophilus cnrz160 pour le traitement et la prevention de l'inflammation intestinale et des desordres associes, chez un individu
FR3065371B1 (fr) Composition pharmaceutique topique comprenant au moins de l'amitriptyline pour le traitement de douleurs neuropathiques peripheriques
FR3073140B1 (fr) Composition pour ameliorer la sante des animaux d'elevage
EA202290048A1 (ru) Лекарственное средство и его применение для лечения бактериальных инфекций, связанных с биопленкой
MA38369B1 (fr) Peptides et compositions pour le traitement d'une lesion de l'articulation
FR3073139B1 (fr) Composition ameliorant le bien-etre des animaux
MX2022004912A (es) Novedoso compuesto de anillo condensado sustituido.
FR3068688B1 (fr) Composition bacterienne et utilisation pour le traitement des eaux usees et le traitement des dechets
FR3072861B1 (fr) Composition antimycotoxine
FR3059237B1 (fr) Utilisation d'une composition bacterienne pour traiter des pathologies animales
MX2021011151A (es) Fitoecdisonas y los derivados de las mismas para su uso en el tratamiento de enfermedades neuromusculares.
SA119410171B1 (ar) طريقة لمنع أو علاج أو تحسين عدوى ميكروبية
WO2018141313A3 (fr) Utilisation de composés fgf-4
EP4159214A4 (fr) Composition pour le traitement, l'amélioration et/ou la prévention de la progression de la papillomatose bovine provoquée par le papillomavirus bovin
FR3073398B1 (fr) Triterpenes pentacycliques dans le traitement d'une pathologie bucco-dentaire

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20191129

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8